Analyst firms · Jefferies · COLL
Jefferies COLL price target and rating history
Collegium Pharmaceutical Inc. (COLL) · Health Care
Jefferies rates Collegium Pharmaceutical Inc. (COLL) Buy with a $44 price target, as of its latest action on Jun 7, 2024. It has published 3 rating actions on COLL since May 2023, including 1 upgrade and 1 downgrade. Across 4 firms with a COLL price target in the last 12 months, the median target is $49.50.
- Current rating
- Buy
- Price target
- $44
- Median target, all firms
- $49.50
- Actions on COLL
- 3
Jefferies price target on COLL
Every Jefferies rating on COLL
- Jun 7, 2024
- Jan 4, 2024
- May 2, 2023
How other firms rate COLL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Oppenheimer | Outperform | $50 | Sep 23, 2026 |
| Truist Securities | Buy | $49 | Sep 9, 2026 |
| Leerink Partners | Outperform | $45 | Sep 9, 2026 |
| Barclays | Overweight | $58 | Dec 9, 2025 |
Questions about Jefferies and COLL
- What is Jefferies's price target for COLL?
- Jefferies's latest stated price target for Collegium Pharmaceutical Inc. (COLL) is $44, from its action on Jun 7, 2024.
- What is Jefferies's rating on COLL?
- Jefferies rates COLL Buy, a bullish rating, as of Jun 7, 2024.
- When did Jefferies last change its view on COLL?
- On Jun 7, 2024, Jefferies upgrades to Buy from Hold, price target $41 to $44.
- How does Jefferies's COLL target compare with other analysts?
- Across 4 firms with a COLL price target in the last 12 months, the median target is $49.50.
More COLL rating histories
All Jefferies ratingsCOLL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.